FEATURED EDITORIAL
Rh disease has been preventable for decades. Yet babies still die worldwide because access, supply, and infrastructure have not caught up.
- Beyond Binder Design: Why AI's Next Frontier Is Designing Multispecific Antibodies
- Drug Discovery AI Has A Ground Truth Problem
- Fragment-Based Drug Discovery 2.0, Part 2: Practical Workflow, Difficult Target Classes, And Emerging Capabilities
- Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit
- Fragment-Based Drug Discovery 2.0, Part 1: Faster, Cleaner Weak-Binding Hit Discovery
- From Path Dependency To Demonstrable Progress: FDA Modernization Act 3.0
- How AI-Powered Automation Is Redefining Pharmaceutical R&D
FEATURED APPLICATION CONTENT
-
Discover how high-throughput electroporation-based screening can compress your CAR-T optimization timeline while delivering reproducible, scale-ready results across multiple donor samples.
-
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.
-
Centralizing data unlocks faster insights, reduces duplicated effort, and improves compliance. By overcoming silos and “dark data,” organizations can enable efficient search, reuse, and analysis.
-
See how existing partnerships with NIH allowed the chance to bring together government, academic, and industry resources through strategic initiatives that streamline processes and maximize benefits.
-
See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.
-
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
-
Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
-
Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
-
Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.
-
Automated structure verification integrated into open-access NMR workflows cuts review time dramatically while maintaining confidence in results. See how smart parameter optimization improves efficiency.
- Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)
- Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit
- Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)
- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 of 3)
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- IQVIA And Medera To Advance Cardiac Gene Therapy And Human-Based Drug Discovery
- Phylo And Chugai Partner To Advance AI Agents In Drug Discovery
- Lilly's Olomorasib Receives U.S. FDA's Breakthrough Therapy Designation For The Treatment Of Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer
- Aravax Awarded FDA Fast Track Designation For PVX108, A Next-Generation Immunotherapy For The Treatment Of Peanut Allergy
- U.S. FDA Grants Orphan Drug Designation To Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (NECs)
- Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI As A Separate Company To Commercialize And Expand Its Multi-Agent AI Co-Scientist Platform For The Transformation Of Medicine
- Lupin Announces The Approval Of Diazepam Injection, USP In The United States
- Henlius Announces IND Approval For Its Innovative PD-L1 ADC HLX43 In Combination With Bevacizumab ± Chemotherapy
- HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation For AI-Designed Candidates
- Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Sasineprocel (ANPD001) To Treat Parkinson's Disease
ARCHIVED NEWSLETTER
- 08.06.26 -- How Research Partners Are Advancing Drug Discovery Solutions
- 08.01.26 -- Drug Discovery Online Best Of July
- 07.28.26 -- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3)
- 07.22.26 -- Advancing Spatial Multiomics For Discovery: From Promise To Practice
- 07.21.26 -- Advancing Spatial Multiomics For Discovery: From Promise To Practice
